Disrupting Substance Use Disorder: The Chemistry of Iboga Alkaloids.
Level 5 - mechanism / opinion, no new human data
Narrative review of chemistry and preclinical literature without human clinical data
PubMed 40895173 · doi:10.1002/ejoc.202400432
What was done
Targeted narrative review discussing synthetic chemical strategies applied to classical and non-classical iboga alkaloids as leads for treating substance use disorder.
What was found
No quantitative synthesis yields or experimental effect sizes are reported in the abstract. The abstract notes that ibogaine reduces opiate, amphetamine, alcohol, and nicotine self-administration in rodents, but presents clinical limitations of cardiotoxicity and hallucinogenicity. Over twenty total syntheses exist for classical family members, with far fewer for recently isolated analogs.
Why it matters
Synthetic methods for novel iboga alkaloids facilitate drug discovery efforts to decouple anti-addictive efficacy from cardiotoxicity and hallucinogenic adverse effects.
Limits
Narrative review structure lacking systematic search criteria, new primary data, or clinical human efficacy measurements.
Cited by
- supports Animal studies show that animals do not self-administer ibogaine.